title: Phase II trial of 4'-epidoxorubicin in advanced gastrointestinal tumor.
abstract: Fourteen Chinese patients with histologically proven advanced gastrointestinal tumors underwent a phase II 4'-epidoxorubicin trial. 6 out of 14 (42%) patients showed static response and the rest showed progression of disease during treatment. The treatment was fairly well tolerated with a mild to moderate degree of nausea, vomiting, alopecia and hematological toxicity.
authors.forename: W
authors.initials: W
authors.lastname: Shiu
authors.forename: S K
authors.initials: SK
authors.lastname: O
authors.forename: S Y
authors.initials: SY
authors.lastname: Tsao
authors.forename: K S
authors.initials: KS
authors.lastname: Woo
authors.forename: C
authors.initials: C
authors.lastname: Martin
mesh_terms: D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D015251:Epirubicin; D004317:Doxorubicin